随着代谢综合征威胁的增加,从成年期早期到中期,关注肾脏健康是必要的。这项研究阐明了由于肾功能异常而导致的死亡风险和寿命损失(YLL)。这是一次回顾,来自2000年至2015年健康体检数据的匹配队列研究。我们确定了12,774名肾功能异常(eGFR<60mL/min/1.73m2)的参与者,并使用倾向评分匹配来确定25,548名肾功能正常(eGFR≥60)的参与者。使用异常和匹配的正常队列之间的预期寿命差异来估计YLL。Cox模型用于估计调整后的死亡风险。蛋白尿和eGFR<60的参与者的估计预期寿命为26.24岁,95%置信区间为(23.96,29.36),17.62(16.37,18.78),30-54、55-64和65-79岁年龄组为11.70(11.02、12.46),分别。与匹配的正常队列相比,蛋白尿和eGFR<60的参与者的估计YLL,分别为17.86(13.41,20.36),12.55(11.41,13.78),三个年龄组为8.31(7.47,9.13)岁,分别。Cox模型对蛋白尿和eGFR<60的参与者与匹配对象的死亡率风险比估计为5.29(3.97,7.05),3.99(3.34,4.75),三个年龄组为3.05(2.62、3.55),分别。肾功能异常会缩短预期寿命,尤其是蛋白尿患者和年轻人。积极健康管理肾功能可减轻疾病负担。
With the increasing threat of metabolic syndromes, a focus on maintaining kidney health from early- to mid-adulthood is necessary. This study elucidates mortality risk and years of life lost (YLLs) due to abnormal renal function. This was a retrospective, matched cohort study from health checkup data from 2000 to 2015. We identified 12,774 participants with abnormal renal function (eGFR < 60 mL/min/1.73 m2) and used propensity score matching to identify 25,548 participants with normal renal function (eGFR ≥ 60). YLLs were estimated using the life expectancy differences between the abnormal and matched normal cohorts. Cox models were used to estimate the adjusted mortality risk. The estimated life expectancy of participants with proteinuria and eGFR < 60 was 26.24 years, with a 95 % confidence interval of (23.96, 29.36), 17.62 (16.37, 18.78), and 11.70 (11.02, 12.46) for age groups of 30 - 54, 55 - 64, and 65 - 79 years, respectively. The estimated YLLs of participants with proteinuria and eGFR < 60, as compared with the matched normal cohort, were 17.86 (13.41, 20.36), 12.55 (11.41, 13.78), and 8.31 (7.47, 9.13) years for the three age groups, respectively. The Cox model estimates of mortality hazard ratios of participants having proteinuria and eGFR < 60 against matched referents were 5.29 (3.97, 7.05), 3.99 (3.34, 4.75), and 3.05 (2.62, 3.55) for the three age groups, respectively. Abnormal renal function shortens life expectancy, particularly in patients with proteinuria and in younger adults. Active health management of renal function can reduce the disease burden.